【桂林三金：控股孙公司BC006单抗注射液新增适应症获得药物临床试验批准】金十数据5月5日讯，桂林三金公告称，公司控股孙公司宝船生物医药科技（上海）有限公司收到国家药品监督管理局核准签发的BC006单抗注射液的临床试验批件，同意本品开展用于特发性肺纤维化适应症的临床试验。该药品此前已获得晚期恶性肿瘤的临床试验批件，目前处于I期临床试验进行中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.